Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.
NTLA filed a patent for "compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfbr2)" on Mon, August 14, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
